Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 281
Selected: 0
NCT IDTitle
NCT03277196A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation
NCT06226454A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993
NCT07378865Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
NCT02015507An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor
NCT04066751The Multicenter Topic Trial
NCT01153542Study of VX-770 on Desipramine
NCT06506773Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)
NCT03745287A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
NCT01821963Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)
NCT00953706Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation
NCT03304028MUCOviscidose EXacerbation Outils Connectés Education Thérapeutique
NCT01561807A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus
NCT01897233Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
NCT03525444A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
NCT00500812A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries
NCT03227471A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
NCT01888393Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects
NCT06392659A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults
NCT03486236A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects
NCT00336479Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C
NCT05882357Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age
NCT00591214Safety and PK Study of MP-424 to Treat Chronic Hepatitis C
NCT01060566Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770
NCT04362761A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy
NCT06861413A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation
NCT04340362Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
NCT00205478Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702
NCT06529796Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment
NCT07074327Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
NCT02669849Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury
NCT02660424A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee
NCT04545515A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes
NCT01516918A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
NCT05356195Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
NCT02742519A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation
NCT00780416Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C
NCT03029455A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis
NCT04353817A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes
NCT00781274Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy
NCT00933283A Study to Investigate the Potential Interaction Between Telaprevir and Methadone, at Steady-State
NCT01253551VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir
NCT03460990A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
NCT03559062A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis
NCT00262483Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C
NCT05579431A Phase 1, First-in-human Study of VX-634
NCT05347394A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants
NCT01886209Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects
NCT04208529A Long-term Follow-up Study in Participants Who Received CTX001
NCT06523595Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults
NCT02516410A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation